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Cumulative risk of cardiovascular disease (CVD) events in 213
young adults patients with familial hypercholesterolemia (FH)
who started statin therapy in childhood (orange) and their 156
affected FH parents (blue) for whom statins were available much
later in life.Familial hypercholesterolemia (FH), a hereditary
disorder of lipoprotein metabolism, results in life-
long increased cholesterol levels and predisposes
to premature cardiovascular disease (CVD) (1). To
prevent premature CVD in adult life, guidelines
advocate initiation of statins in childhood (2). Since
the introduction of statins in 1988, this treatment has
proven highly effective in lowering low-density li-
poprotein cholesterol levels for CVD prevention (3).
Until now, no randomized or controlled data exist
with regard to the primary prevention of CVD in FH
patients, because it was considered unethical to
withhold therapy. However, the natural history of the
disease in the untreated parents can be compared
with the history of their long-term treated FH chil-
dren, at least until the age that the children reached
at the end of follow-up. In this present study, we
evaluated the consequences for cardiovascular out-
comes of at least 10 years of statin treatment in young
adults with FH and compared these outcomes in their
affected parents for whom statins were available
much later in life.
In a long-term follow-up study, we determined the
incidence of cardiovascular events and mortality in
FH patients who initiated statin therapy during
childhood. Subjects were children with FH, random-
ized between 1997 and 1999 into a 2-year, double-
blind and placebo-controlled trial, evaluating pra-
vastatin (4). After the trial, all children received pra-
vastatin and were eligible for the current study after
at least 10 years of follow-up. From the original
cohort of 214 FH children, 1 boy died after a trafﬁc
accident at the age of 15 years. Mean age (SD) of the
remaining 213 now young adults was 24.0  3.2 years
(range 18 to 30 years), and 100 (46.9%) were male.
Statin therapy was initiated at a mean age of 14.0 
3.1 years. We contacted all 213 young adults to gaininformation on CVD events. Detailed information on
medical history and other cardiovascular risk factors
was available from 194 young adult FH subjects.
Lipid-lowering therapy was still used by 163 (84.0%)
subjects, and mean treatment duration was 10.1  1.2
years (5). With respect to risk factors, 1 patient had
developed diabetes, and 1 was treated for hyperten-
sion. Furthermore, 54 (27.8%) stated that they were
current smokers.
To determine the consequences of statins for the
natural history of FH, we subsequently evaluated
data of their affected parents in the ﬁrst 30 years of
their lives. The children originated from 156 different
families, with 92 (59.0%) affected FH fathers and 64
(41.0%) affected FH mothers. Of these, 14 parents
were already deceased. The mean age of the 142
remaining parents was 53.9 (6.4) years. On the basis
of the assumption that statins were introduced in
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4561988, statin therapy was available for 43 (30.3%) of all
FH parents before they were 30 years of age. For the
remaining 99 (69.7%) parents, statins could have
been initiated at the earliest after the age of 30 years.
In the group of affected parents, 64 (41.6%) had a
cardiovascular event during follow-up, mostly a
myocardial infarction (n ¼ 43; 67.2%). At the age of
30 years, the cumulative CVD survival in the parental
FH group was near 90% (Figure 1). None of the
mothers had died before the age of 30, whereas
the cumulative incidence of death due to CVD of the
fathers was almost 5%. The youngest parent with a
myocardial infarction was 20 years old and deceased
from the consequences at the age of 23 years.
Our ﬁndings that FH parents experiencing cardio-
vascular events at a younger age than those FH chil-
dren treated from childhood onwards are in line with
the results of Kusters et al. (5). They found in the
same study population that long-term statin treat-
ment initiated during childhood was associated with
normalization of carotid intima–media thickness
(IMT) progression in FH subjects. Furthermore,
earlier initiation of statin therapy was associated with
thinner carotid IMT at follow-up. Because carotid IMT
is an established marker of early atherosclerosis,
these results support the pivotal role of statins in the
inhibition of the development of early atherosclerotic
lesions in FH children.
Altogether, our results suggest that initiation of
statin therapy in childhood may be effective in the
prevention of very premature CVD and cardiovascular
mortality. These ﬁndings underline the importance of
early diagnosis and treatment of FH patients that
should include initiation of statin treatment as well
as modulation of other major CVD risk factors,
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1055–7.Association
of Hemoglobin A1c Levels
With Cardiovascular
Disease and Mortality
in Chinese Patients
With DiabetesAmong diabetic patients, hemoglobin A1c (HbA1c) is
an important indicator of glycemic control and,
together with blood pressure and cholesterol, is an
indicator for risk of complications, including cardio-
vascular disease (CVD) and mortality. At present,
there is no universal consensus on the optimal HbA1c
level. Despite this, most international guidelines
include a recommended HbA1c target range or level
as a treatment goal. Several studies have identiﬁed
a J-shaped curvilinear relationship between HbA1c
and CVD incidence and all-cause mortality, but
such a relationship has not yet been conﬁrmed in a
Chinese population (1). There are substantial dif-
ferences in disease risks across racial and ethnic
groups due to genetic and environmental factors
including life-style and health behaviors, and thus,
previous results from Western studies may not be
transferable to a Chinese population (2). We sought
to examine the association among mean HbA1c,
CVD events, and mortality among Chinese primary
care patients with type 2 diabetes mellitus (T2DM)
in Hong Kong.
